biostudies-literatureUnknown21(6)Koehler PSevere acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is eitherThe Lancet. Infectious diseasese149-e162https://www.ebi.ac.uk/biostudies/studies/S-EPMC7833078biostudies-literatureDefining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.PMC7833078Infectious Diseases Working Party of the German Society for Haematology and Medical OncologyLass-Florl CGangneux JPChakrabarti AISHAM Pan Africa Mycology Working GroupInternational Society for Human Animal MycologyHoenigl MKlimko NBruggemann RChen SCACornely OAInfectious Disease CanadaMedical Mycology Society of NigeriaOladele ROZhu LPKoehler PPatterson TFINFOCUS LATAM/ISHAM Working GroupBoll BMedical Mycology Society of China Medicine Education AssociationAssociation of Medical MicrobiologyPersigehl TVerweij PEInterregional Association of Clinical Microbiology and Antimicrobial ChemotherapyPerfect JRAsia Fungal Working GroupColombo ALMeis JFVinh DCBassetti MOstrosky-Zeichner LEuropean Society for Clinical MicrobiologyEuropean Confederation of Medical MycologyInfectious Diseases Fungal Infection Study GroupESCMID Study Group for Infections in Critically Ill PatientsWhite PLfalseDefining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either2021-01-01T00:00:00Z2021 Jun2025-04-05T00:14:25.788Z2021-02-21T02:31:27ZS-EPMC78330783333301210.1016/S1473-3099(20)30847-1